

## **U.S. Army North (Fifth Army)**

"Strength of the Nation"

## **Press Release**

Headquarters, U.S. Army North (Fifth Army) Office of Public Affairs 1400 E Grayson St., Building 44 San Antonio. Texas 78208



FOR IMMEDIATE RELEASE

November 2, 2021

Release No. 21-11-001

## ARNORTH military hospital support to FEMA begins in Utah, continues in three states

**SAN ANTONIO, Texas** - At the request of the Federal Emergency Management Agency, one monoclonal antibody infusion team, consisting of approximately 15 active duty military medical personnel, deployed to Utah.

U.S. Army North, under U.S. Northern Command's oversight, will provide operational command of the team.

"These fifteen military medical personnel, who comprise the first monoclonal antibody infusion team the Department of Defense has deployed, join approximately ten thousand others who have supported the whole-of-government response to the COVID-19 pandemic since March 2020," said Lt. Gen. John R. Evans, Jr., ARNORTH commander. "Whether it is defending the nation, or defeating this virus and saving lives, we will use every tool in our arsenal to protect the American people."

The military medical personnel will include a medical doctor, nurses, and other healthcare workers from the U.S. Air Force.

This team, who will support Intermountain St. George Regional Hospital in St. George, Utah, joins four other teams currently working in four hospitals – one in Alabama, one in Idaho, and two in Washington.

ARNORTH is the joint force land component command of USNORTHCOM.

For additional information, contact ARNORTH Public Affairs office at 210-428-9835 or <a href="mailto:usarmy.jbsa.arnorth.mbx.pao@mail.mil">usarmy.jbsa.arnorth.mbx.pao@mail.mil</a>; for photos and/or videos, visit: <a href="https://www.dvidshub.net/unit/DSFC19">https://www.dvidshub.net/unit/DSFC19</a>.

- 30 -

In November 2020, the U.S. Food and Drug Administration approved the emergency use authorization of casirivimab and imdevimab to be administered together through intravenous infusion for the treatment of COVID-19 symptoms. This infusion is used to treat mild to moderate COVID symptoms, effectively reducing the amount of hospitalizations and emergency room admissions.

For additional information about the infusion, see the FDA's fact sheet at <a href="https://www.fda.gov/media/143893/download">https://www.fda.gov/media/143893/download</a>.